APSR IDI Online KlikPDPI
APSR IDI Online KlikPDPI Halaman Admin Forum Umum Facebook Page Twitter Instagram Youtube
Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF®, a Phase II randomised, double-
PDPI Sulawesi Selatan & Utara, 30 Sep 2024 05:54:58

James D. Chalmers, Michal Shteinberg, Marcus A. Mall, Anne E. O'Donnell, Henrik Watz, Abhya Gupta, Edith Frahm, Anastasia Eleftheraki, Johanna Rauch, Sanjay H. Chotirmall, April W. Armstrong, Peter Eickholz, Naoki Hasegawa, Wiebke Sauter, Pamela J. McShane
European Respiratory Journal 2024; DOI: 10.1183/13993003.01551-2024 

Abstract

Bronchiectasis is characterised by uncontrolled neutrophil serine protease (NSP) activity. Cathepsin C (CatC; dipeptidyl peptidase 1) activates NSPs during neutrophil maturation. CatC inhibitors can potentially reduce neutrophil-mediated lung damage. This Phase II, randomised, double-blind, placebo-controlled trial (AIRLEAF®; NCT05238675) evaluated efficacy, safety and optimal dosing of BI 1291583, a novel, reversible CatC inhibitor, in adults with bronchiectasis.

In total, 322 participants were randomised (2:1:1:2) to receive one of three oral doses of BI 1291583 (1 mg/2.5 mg/5 mg) or placebo for 24 to 48 weeks. A multiple comparison procedure and modelling approach was used to demonstrate a non-flat dose–response curve based on the time to first pulmonary exacerbation up to Week 48. In addition, efficacy of individual BI 1291583 doses was evaluated based on the frequency of exacerbations, severe exacerbations (fatal or leading to hospitalisation and/or intravenous antibiotic administration), lung function and quality of life.

A significant dose-dependent benefit of BI 1291583 over placebo was established based on time to first exacerbation (shape: Emax; adjusted p-value: 0.0448). Treatment with BI 1291583 5 mg and 2.5 mg numerically reduced the risk of an exacerbation compared with placebo (hazard ratios: 0.71 and 0.66, 95% CIs 0.48–1.05 and 0.40–1.08; both p>0.05). BI 1291583 2.5 mg showed numerically better efficacy compared with 5 mg across several endpoints; 1 mg was similar to placebo. The safety profile of BI 1291583 was similar to placebo.

Treatment with BI 1291583 resulted in a reduction in the risk of experiencing an exacerbation in adults with bronchiectasis.

Juara III - PDPI Cab Malang
Uploaded on March 27, 2022